|
|
|
|
|
Benazepril
drug data and news
Benazepril drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Benazepril | ||
| Brand Names/Synonyms | Benazepril; Benazepril Hcl; Benazepril Hydrochloride; Benazeprilum [Latin]; Briem; Cibacen; Cibacene; Lotensin | ||
| Indication | For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. | ||
| Mechanism Of Action | Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Benazeprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin. | ||
| Benazepril News (When available) |
The Evolving Chinese Health Care System Feb 22, 2006 ACE Inhibitors Treat Kidney Disease Jan 11, 2006 ACE Inhibitors Slow Progression of Chronic Renal Disease Jan 11, 2006 Secondary Mania in Older Adults Nov 13, 2005 Ranbaxy Receives Final Approval To Market Benazepril Hydrochloride ... Sep 9, 2005 Ranbaxy gets US’ FDA nod Sep 14, 2005 Ranbaxy gets USFDA approval for high BP drug Sep 14, 2005 Ranbaxy gets US FDA approval for high BP drug Sep 14, 2005 Ranbaxy obtains US FDA approval for high BP drug Sep 14, 2005 Analysis: Blood-pressure guideline blurred Sep 16, 2005 Indices close marginally lower on profit booking Sep 14, 2005 (PRN) - The Ultimate Advantage in Healing a Broken Heart or ... Sep 9, 2005 Race influences prostate cancer behavior Jul 29, 2005 Patient education the key to treating diabetes Jun 29, 2005 Cardiovascular Outcomes and Antihypertensive Drug Treatment in ... Apr 5, 2005 Pharma cos face hurdles in going global Mar 13, 2005 BCBSNC Launches New Prescription Drug Savings Initiative Feb 17, 2005 | ||
| Dosage Forms | Tablets containing 5, 10, 20 and 40 mg of benazepril. | ||
| Drug_Category | Antihypertensive Agents; Angiotensin-converting Enzyme Inhibitors; ATC:C09AA07 | ||
| Absorption | Peak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract. | ||
| Interactions |
-->Interactions for Benazepril: Diuretics Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin. The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin. If this is not possible, the starting dose should be reduced. Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patient’s serum potassium should be monitored frequently. Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants. Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased. Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine. Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions. Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system.
| ||
| Toxicity | Swelling of face, mouth, hands, or feet; trouble in swallowing or breathing (sudden); hoarseness; fever and chills. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-[4-(1-ethoxycarbonyl-3-phenyl-propyl)amino-5-oxo-6-azabicyclo[5.4.0]undeca-7,9,11-trien-6-yl]ethanoicacid | ||
| Chemical Formula | C24H28N2O5 | ||
| Molecular Weight | 424.49 g/mol | ||
| Smiles String | CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O | ||
| Melting Point | 148-149 °C | ||
| Water Solubility | 2.229 mg/L | ||
| State | white to off-white cystalline powder | ||
| LogP/Hphobicity | 3.217 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, Benazeprilat. | ||
| Half Life | 10-11 hours | ||
| Protein Binding [%] | 96.70% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Benazepril.html http://www.rxlist.com/cgi/generic/benaz.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00063 | ||
| CAS Registry Number | 86541-75-5 | ||
| KEGG Compound ID | C06843 | ||
| PubChem ID | SID:205187 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 885835 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |